Corcept Therapeutics (CORT) Research & Development (2010 - 2026)
Corcept Therapeutics (CORT) posted Research & Development of $53.9 million for Q2 2026, down 18.68% sequentially from $66.3 million in Q1 2026, and down 10.88% YoY from $60.5 million in Q2 2025.
Corcept Therapeutics (CORT) Research & Development (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Research & Development for 17 years, with the latest figure at $53.9 million in Q2 2026.
- Quarterly Research & Development fell 10.88% year-over-year to $53.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $253.9 million (up 1.2% YoY) and the FY2025 annual result came in at $254.9 million, up 3.25% from the prior year.
- Research & Development slipped to $53.9 million in Q2 2026 per CORT's latest filing, from $66.3 million in the prior quarter.
- Over five years, Research & Development peaked at $70.3 million in Q4 2024 and troughed at $28.1 million in Q1 2022.
- A 5-year average of $52.1 million and a median of $56.6 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2026: Research & Development soared 48.85% in 2023, then dropped 10.88% in 2026.
- Over 5 years, Research & Development stood at $36.8 million in 2022, then jumped by 48.85% to $54.7 million in 2023, then gained by 28.5% to $70.3 million in 2024, then fell by 7.74% to $64.9 million in 2025, then dropped by 16.91% to $53.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $53.9 million, $66.3 million, and $64.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 53.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.89 Mn |
| Mar 31, 2026 | 66.27 Mn |
| Dec 31, 2025 | 64.86 Mn |
| Sep 30, 2025 | 68.85 Mn |
| Jun 30, 2025 | 60.47 Mn |
| Mar 31, 2025 | 60.74 Mn |
| Dec 31, 2024 | 70.30 Mn |
| Sep 30, 2024 | 59.34 Mn |
| Jun 30, 2024 | 58.75 Mn |
| Mar 31, 2024 | 58.51 Mn |
| Dec 31, 2023 | 54.71 Mn |
| Sep 30, 2023 | 45.52 Mn |
| Jun 30, 2023 | 43.28 Mn |
| Mar 31, 2023 | 40.85 Mn |
| Dec 31, 2022 | 36.75 Mn |
| Sep 30, 2022 | 33.29 Mn |
| Jun 30, 2022 | 32.83 Mn |
| Mar 31, 2022 | 28.12 Mn |
| Dec 31, 2021 | 28.52 Mn |
| Sep 30, 2021 | 28.09 Mn |